| |
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”) today announced that it has entered into an agreement with Shoppers Drug Mart Inc. (“Shoppers Drug Mart”) for the over-the-counter (“OTC”) sale of the HeartCheck™ ECG PEN device in pharmacies across Canada. The HeartCheck™ ECG PEN has passed regulatory reviews by both Health Canada and the US Food and Drug Administration as the only OTC ECG displaying device personal heart-health monitoring solution available without a physician’s prescription.
The HeartCheck™ PEN will be made available in approximately 602 Shoppers Drug Mart Pharmacies by February 2015 which will coincide with the start of Heart Month. The product will be placed within the diabetes and high blood pressure monitoring devices section of the store planogram.
The HeartCheck™ PEN ECG can store 20 ECG recordings in memory which can be transferred to a computer for review and management. Consumers purchasing the device will have access to the Company’s free GEMS™ Home software and a free first ECG interpretation through the CardioComm Solutions’ SMART Monitoring ECG service. Sales will target those consumers, and their family, who are interested in the preservation of their heart health as well as those at risk for developing arrhythmias due to underlying conditions, especially prior heart attack, prior cardiac surgery, high blood pressure, high cholesterol, heart failure, diabetes and those taking medications that cause arrhythmias.
CardioComm Solutions has been working with pharmacy banner groups to expand introduction of ECG self-screening and monitoring into the consumer market. The HeartCheck™ PEN is as a groundbreaking and proven medical device that meets the pharmacies’ objective of enhancing personalized heart-health monitoring and betterment of their customers’ health.
More information regarding the HeartCheck™ products and SMART monitoring solutions is available at the Company’s web site www.theheartcheck.com.
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
forward-looking information.
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Obligations).
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
|
